AbbVie, Gubra and obesity

AbbVie enters into almost $2B contract with Gubra for obsesity drug
Bloomberg reports the obesity drug market is expected to reach as much as $130 billion in annual sales by 2030.
AbbVie enters obesity space with $2.3bn Gubra deal
AbbVie is entering the obesity treatment market with a $2.3bn licensing agreement to acquire global rights to GUB014295, a long-acting amylin analogue developed by Danish biotech Gubra. Announced on 3 March,
Abbvie enters $2.2B deal for Gubra’s amylin obesity drug
Abbvie Inc. is buying into the obesity fray in a potential $1.875 billion development and commercialization agreement with Danish peptide drug discovery specialist Gubra A/S. In addition, there will be a $350 million up-front payment as Abbvie takes over the reins of GUB-014295 (referred to as Gubamy),
AbbVie, Gubra in Obesity-Drug License Pact Potentially Worth More Than $2 Billion
AbbVie is jumping into the burgeoning obesity field, striking a license agreement with Gubra that is potentially worth more than $2 billion to the Danish drug-discovery and contract-research-services company.
AbbVie enters obesity drug market with Danish drugmaker
AbbVie has signed a licensing deal with Gubra A/S to develop an obesity drug, marking the North Chicago company's first foray into the obesity market.
AbbVie Steps Into The Ring In The Obesity Drug Wars
AbbVie's strategic move into the obesity market through a partnership with Gubra A/S shows potential but won't impact revenue. Click to read why ABBV is a Hold.
AbbVie Enters The Obesity Arena. Why It's Paying Up To $2.23 Billion.
AbbVie inked a licensing deal Monday worth up to $2.23 billion for an amylin-targeting obesity treatment from Denmark-based Gubra A/S.
AbbVie steps into the obesity drug race, licensing medicine from Danish firm
The obesity medicine field has gained a new entrant, with AbbVie licensing an experimental drug from a Danish company.
BioPharma Dive3d
AbbVie gets into obesity with $350M deal for once-weekly shot
A licensing deal with Denmark’s Gubra gives the immunology giant control of an experimental therapy that could compete with ...
Fierce Biotech3d
AbbVie pays Gubra $350M to make late play for obesity space
AbbVie is paying $350 million to join the obesity race. The outlay, plus up to $1.875 billion in milestones, has landed the ...
PharmExec3d
AbbVie, Gubra Strike Deal to Develop Novel Weight Loss Treatment
Under terms of the deal, Gubra will receive an initial $350 million payment and could earn up to $1.875 billion more in ...
AbbVie, Gubra announce license agreement to develop GUB014295
AbbVie (ABBV) and Gubra announced a license agreement to develop GUB014295, a long-acting amylin analog for the treatment of obesity. Under the ...
Wall Street Lunch: Ghost Of Stagflation Alarms Investors
The stagflation specter is spooking traders today, wiping out the risk-on move that was buoying stocks and weighing on board ...
Healthy Returns: AbbVie is the newest potential weight loss drug market player
AbbVie will pay up to $2.2 billion to develop Danish drugmaker Gubra's obesity drug. AI takes center stage at HIMSS ...
Gubra A/S: Annual Report 2024: Excellent performance across Gubra
Gubra released its Annual Report for 2024. Significant progress was made in 2024 across several R&D projects, not the least by advancement of the anti-obesity Amylin program where positive topline ...